The abstract submission period for the 2023 Annual Meeting is now closed.
The AAHKS Program Committee invites unpublished research study abstracts for either podium or poster presentations. Authors of abstracts selected for podium presentations will have the opportunity to submit draft manuscripts for consideration of the James A. Rand Young Investigator’s Award, AAHKS Surgical Techniques and Technologies Award or AAHKS Clinical Research Award. Authors also will have the opportunity to submit manuscripts for the Journal of Arthroplasty (JOA) Proceedings of the Annual Meeting.
Abstracts must be 300 words or less. Individuals may submit multiple abstracts and will be able to edit submissions until the submission deadline, 11:59 p.m. Central on Thursday, June 1.
- In order to create and submit an abstract, log in with your AAHKS credentials or create a new account on the submission website, http://submit.aahks.net
- Ensure that the names and e-mail addresses of your co-authors are entered. All of the co-authors are required to submit disclosures. If any author disclosures are missing, the abstract will be withdrawn from the final program.
- Abstracts may be submitted if you previously presented a paper at a national/international meeting; however, the work must be unpublished as of the start of the AAHKS Annual Meeting.
- Podium presenter must be an Arthroplasty Fellow or more senior surgeon/PhD at the time of the meeting.
- Problem statement
- Statement of purpose/hypothesis of the study
- Study design (e.g., prospective-randomized, prospective cohort, retrospective cohort or case control)
- Sample size estimate for prospective studies
- Study group: inclusion/exclusion criteria, demographics, follow-up
- Data collection methods and statistical methods
- Sufficient report of the data and results of the study
- P-values required for statements of statistical significance
- Statements of no significant difference should include an assessment of statistical power
- If inadequate sample size, state “with the numbers available for study”
- What did the study show?
- Does the data support the conclusion and did the study answer the research question?
Selection and Grading Process
All abstracts will be reviewed in a blinded fashion. Each abstract in the given category will be evaluated and graded by five independent reviewers. The abstracts will be graded on a 25-point scale. Each score will be tallied, and scores will be averaged. The abstracts with the highest scores in each category will be selected for podium presentations. Several next-highest scored abstracts will be selected as poster presentations.
The grading scale assigns five maximum points for each of the following:
- Topic: Importance and originality.
- Introduction: Purpose of paper and hypothesis is clearly stated.
- Methods: Study design (e.g., prospective-randomized, prospective cohort, retrospective cohort or case control) is clearly stated. Power analysis estimates for prospective studies are included. Study group is clearly described. Inclusion/exclusion criteria, demographics, and follow-up are noted. Data collection methods and statistical methods are described.
- Results: Results and associated data must be clearly and precisely described; appropriate p-values should be given.
- Conclusion: Study findings should be restated. Conclusion must indicate whether the data supported the study findings.
Disclosure and Conflict of Interest
Authors, co-authors, presenters and other contributors to the educational content must submit their disclosure information on AAHKS disclosure site, https://disclosure.aahks.net/login/user. The disclosures of financial relationships with commercial interests must be completed by June 1, 2023. Submissions where authors fail to disclose will be withdrawn from the program.
If a device or drug requiring FDA approval is included in the educational content, the content must include the FDA clearance status of the medical devices and pharmaceuticals for the uses discussed or described. “Off label” uses of a device or pharmaceutical may be described so long as the lack of FDA clearance for such uses is also disclosed. Posters exhibiting a Class III device or pharmaceutical require signage indicating the FDA status of the product.
Ensure that educational content complies with HIPAA (Health Insurance Portability and Accountability Act) to protect patient rights and confidentiality.
Abstracts: March 1 – June 1
Symposia: March 1 – May 1